Search publications
Title: Prostate cancer screening for men aged 75 to 84 years in New South Wales
Authors: Carmichael LK; Goldsbury DE; O'Connell DL
Categories: Cancer Type - Prostate Cancer
Cancer Control, Survivorship, and Outcomes Research - Resources and Infrastructure
Keywords: Aged; cancer; New South Wales; prostate; Research; screening; Wales
Year: 2013
Journal Title: Australian and New Zealand Journal of Public Health
Volume: 37
Issue: 5
Page number start: 492
Page number end: 494
Abstract: In 2012, an international randomised controlled trial demonstrated that 11 years after screening with the prostate‐specific antigen (PSA) test for prostate cancer there was a population‐wide mortality benefit from having had the test, but that this benefit may be outweighed by the harms associated with testing and treatment.1 In Australia, the Royal Australian College of General Practitioners does not recommend screening asymptomatic men older than 75 years, due to the long natural history of untreated localised prostate cancer, the impact of competing causes of death, the increase in false‐positive results with age and adverse effects of radical treatment.2 However – despite these recommendations – in a recent Australian study, 47% of men aged 75–84 years reported having had a PSA test in the previous two years.3 We used Australian Medicare claims data to determine the screening status of men aged 75–84 years with no prior diagnosis of prostate cancer and examined demographic, lifestyle and health‐related factors associated with prostate cancer screening.
Programme: Health Services Research
Division: Cancer Research Division
Funding Body: This study was funded by National Health and Medical Research Council Project Grant #337601 and Cancer Council NSW.
DOI: 10.1111/1753-6405.12115
URI: http://researchpubs.cancercouncil.com.au/cancercounciljspui/handle/1/1586
Appears in Collections:Research Articles

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.